FPR2 and non-small cell lung carcinoma: Hence, ALX/FPR2 agonists have the potential to influence the neutrophil to lymphocyte ratio (NLR), which is a prognostic marker in NSCLC, where elevated NLR levels associate with poorer overall survival in NSCLC [14,15].